Assessing Spillover Effects of Medications for Opioid Use Disorder on HIV Risk Behaviors among a Network of People Who Inject Drugs.
(2024 Jun)
Stats (Basel) 7(2): 549-575
Puleo J, Buchanan A, Katenka N, Halloran ME, Friedman SR, Nikolopoulos G

Evaluating the Test-Negative Design for COVID-19 Vaccine Effectiveness Using Randomized Trial Data: A Secondary Cross-Protocol Analysis of 5 Randomized Clinical Trials.
(2025 May 1)
JAMA Netw Open 8(5): e2512763
Andrews LIB, Halloran ME, Neuzil KM, van der Laan L, Huang Y, Andriesen J, Patel M, Fisher LH, Janes H, Rouphael N, Walsh SR, Theodore DA, Tieu HV, Sobieszczyk M, El Sahly HM, Baden LR, Falsey AR, Campbell TB, Kelley CF, Healy CM, Immergluck L, Luft B, Hirsch I, de Bruyn G, Truyers C, Priddy F, Sumner KM, Flannery B, Follmann D, Gilbert PB, COVID-19 Prevention Network (CoVPN)

Designs for Vaccine Studies.
(2025 Mar)
Annu Rev Stat Appl 12(): 1-18
Halloran ME

Estimating transmissibility of Zika virus in Colombia in the presence of surveillance bias.
(2025 May 8)
Nat Commun 16(1): 4299
Tsang TK, Rojas DP, Xu F, Xu Y, Zhu X, Halloran ME, Longini IM, Yang Y

Analysis methods for covariate-constrained cluster randomized trials with time-to-event outcomes.
(2025 Jan 22)
BMC Med Res Methodol 25(1): 16
Crisp AM, Halloran ME, Hitchings MDT, Longini IM, Dean NE